Bionic ear manufacturer Cochlear (ASX: COH) has received FDA clearance to market its Osia 2 bone implant in the US for those older than 12 years of age with conductive hearing loss, mixed hearing loss and single-sided sensorineural deafness.
Unlike its traditional implant which stimulates the cochlea with electrical signals, the Osia is an implant that bypasses damaged parts of the ear to send sound vibrations direct to the cochlea.
The Sydney company will begin Osia’s US market rollout in the new year with other countries to follow local regulatory approvals.
The new implant is manufactured by Cochlear Bone Anchored Solutions of Sweden.
In June Cochlear received approval for the Nucleus Profile Plus cochlear implant, which is now on sale in the US.
Picture: Guy’s and St Thomas’ NHS Foundation Trust
Subscribe to our free @AuManufacturing newsletter here.